Gamma-aminobutyric acid type A receptor alpha-2 and alpha-3 subunit (GABAA receptor α2 subunit (GABRA2), GABAA receptor α3 subunit (GABRA3))

The gamma-aminobutyric acid type A receptor (GABAA receptor) is a pentameric ligand-gated chloride ion channel responsible for mediating the majority of fast inhibitory neurotransmission in the central nervous system[1][2][4][8]. Each functional receptor is assembled from five subunits selected from multiple possible isoforms; the α2 and α3 subunits represent specific gene products (GABRA2, GABRA3) that, when incorporated into the receptor complex, determine its pharmacological profile and functional properties. Receptors containing the α2 and α3 subunits are highly expressed in specific brain regions and are important therapeutic targets for anxiolytic, anticonvulsant, muscle relaxant, and hypnotic drugs[4][5][6][7]. Benzodiazepines and related compounds exert subtype-selective effects via interactions at the benzodiazepine binding site formed by alpha/gamma subunit interfaces, with α2- and α3-containing receptors particularly implicated in anxiolytic and muscle relaxant actions[7]. Dysfunction or altered expression of these subunits has been implicated in a range of neurological and neuropsychiatric disorders, making them important both as drug targets and research biomarkers[4][7][8].

Other names

GABRA2 (alpha-2)GABRA3 (alpha-3)GABAA α2GABAA α3GABA(A) receptor alpha-2/alpha-3

Positive allosteric modulation (benzodiazepines, Z-drugs) Agonism at chloride channel (barbiturates, gaboxadol) Allosteric modulation of GABA-induced channel opening (etomidate, propofol) Antagonism (flumazenil)